The nominator is interested in using an updated systematic review on the use of payment models by health systems-what data show bundled payments work/don't work to inform the policies and practices of health systems and result in the increase the quality and efficiency of healthcare.
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Background
In 2012 AHRQ published Evidence Report No. 208, Bundled Payment: Effects on Health Care Spending and Quality by the RAND Evidence-based Practice Center. (1) The report reviewed 58 studies through 2011 and reached the following conclusion: "In summary, the introduction of bundled payment was associated with (1) reductions in health care spending and utilization, and (2) inconsistent and generally small effects on quality measures. These findings were consistent across different bundled payment programs and settings, but the strength of the body of evidence was rated as low, due mainly to concerns about bias and residual confounding."
On July 25, 2016, the Department of Health & Human Services (HHS) announced the Bundled Payments for Care Improvement (BPCI) program that included up to 48 types of care episodes or bundled payment models. (2) The Administration's goal with these initiatives is to make progress to shift Medicare payments from quantity to quality by creating strong incentives for hospitals to deliver better care at a lower cost. These models would reward hospitals that work together with physicians and other providers to avoid complications, prevent hospital readmissions, and speed recovery. CMS has determined that some bundled and other risk-bearing payment models (including Chronic Care for Joint Replacement, Oncology Care Model, and End-Stage Renal Disease model) qualify as Advanced Alternative Payment models (APMs). Clinicians who participate in these models are eligible to receive a 5% bonus on all their Medicare Part B billing charges for each year of participation. This incentive has driven many practices and providers to invest in bundled payments. This program is slated to end September 2018.
Healthcare systems face many uncertainties regarding BPs to include:  Decisions on whether to participate in BPs  What factors are associated with successful BP models  Which disease specific models to implement,  How to define the bundle,  How to implement them, how to structure payments,  Which providers and institutions to include (i.e. single vs. multiple)  Whether payments should be retrospective or prospective  How to handle gain (risk) sharing (e.g. "upcoding" and "unbundling")
Nominator and Stakeholder Engagement:
The topic was discussed with the nominator who expressed interest in a review in this area and the relevance and value to their health systems membership. According to the nominator, the observation that "CMS is actively engaged in developing a new iteration of this program makes this brief timely and applicable as health systems think about how to participate in BPCI's redesign and other commercial models." They believe that the 2012 KQs are generally relevant to their membership given that new bundled payment (BP) models continue to be developed and evolve in terms of complexity.
Many members participate in Medicare ACOs including the Medicare Shared Savings Program and the Next Generation ACO Model. These models often complicate or pull eligible patients out of bundled payment initiatives--some health systems see participation in ACOs as a key contextual factor mediating their willingness to participate in bundled payments.
The key questions for this nomination are: Key Question 1.
What does the evidence show on the effects of bundled payment versus usual (predominantly fee-for-service) payment on health care spending and quality measures? Key Question 2. Does the evidence show differences in the effects of bundled payment systems by key design features?
Key Question 3. Does the evidence show differences in the effects of bundled payment systems by key contextual factors?
To define the inclusion criteria for the key questions we specify the population, interventions, comparators, outcomes (PICOS) of interest (Table 1) .
Key Questions
What does the evidence show on the effects of bundled payment versus usual (predominantly feefor-service) payment on health care spending and quality measures? 
Methods
We assessed nomination Bundled Payments: Effects on Health Care Spending and Quality, for priority for a systematic review or other AHRQ EHC report with a hierarchical process using established selection criteria (Appendix A). Assessment of each criteria determined the need for evaluation of the next one. 1. Determine the appropriateness of the nominated topic for inclusion in the EHC program. 2. Establish the overall importance of a potential topic as representing a health or healthcare issue in the United States. 3. Determine the desirability of new evidence review by examining whether a new systematic review or other AHRQ product would be duplicative. 4. Assess the potential impact a new systematic review or other AHRQ product. 5. Assess whether the current state of the evidence allows for a systematic review or other AHRQ product (feasibility). 6. Determine the potential value of a new systematic review or other AHRQ product.
Appropriateness and Importance
We assessed the nomination for appropriateness and importance.
Desirability of New Review/Duplication
We searched for high quality, completed or in-process evidence reviews published in the last three years on the key questions of the nomination. See Appendix B for sources searched.
Impact of a New Evidence Review
The impact of a new evidence review was qualitatively assessed by analyzing the current standard of care, the existence of potential knowledge gaps, and practice variation. We considered whether it was possible for this review to influence the current state of practice through various dissemination pathways (practice recommendation, clinical guidelines, etc.).
Feasibility of New Evidence Review
We conducted a literature search in PubMed from Jan 2011 to Dec 2017. We reviewed all identified titles and abstracts for inclusion and classified identified studies by study design, to assess the size and scope of a potential evidence review. See Appendix C for the PubMed search strategy.
Value
We assessed the nomination for value. We considered whether or not the clinical, consumer, or policymaking context had the potential to respond with evidence-based change; and if a partner organization would use this evidence review to influence practice.
Compilation of Findings
We constructed a table with the selection criteria and our assessments (Appendix A).
Results
Appropriateness and Importance
This is an appropriate and important topic, specifically the effects of bundled payment models on health care spending and quality. Health care costs are high and rising in absolute terms and as a percentage of gross domestic product. Quality of health care is also a significant concern. Health systems face uncertainty in how to choose, design and implement bundled payment models. Selection of payment models affects heath care financing decisions for a large, vulnerable population including people covered by MEDICARE and MEDICAID.
Desirability of New Review/Duplication
A new evidence review on bundled payment models would not be duplicative of an existing product. No systematic reviews were identified that were specific to bundled payments across clinical conditions, providers and institutions covered in key questions 1 to 3. The PROSPERO database identified two protocols (3, 4) related to bundled payments, but these also did not cover the breadth of clinical conditions of the nomination.
Impact of a New Evidence Review
A new systematic review on the effects of bundled payments may have a high impact. Currently the effect of bundled payment models compared to usual payment models (e.g. fee for service, capitation) in terms of cost and quality is unclear due to limitations in the evidence base. There is also variation in payment models (e.g. clinical conditions, financial and non-financial incentives, organizational, market and patient characteristics) across payers and health systems due to limited study designs and outcome data. The optimal configuration for bundled payments is unknown.
Feasibility of a New Evidence Review
A new evidence review examining bundled payment models is feasible. We identified 21 studies of relevance to the topic (Table 2) . Eleven studies were identified through PubMed (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) (15); 7 additional studies through the Cochrane Library Central Register of Controlled Trials (16) (17) (18) (19) (20) (21) (6); and 3 in clinicaltrials.gov (22) (23) (24). Specific types of bundles covered in these studies included joint replacement (5) , hip and other fractures (2), newborn screening, outpatient therapy, renal dialysis (3), spinal surgery, diabetic amputations, cancer pharmacotherapy, sub-acute home rehabilitation, acute coronary syndrome and heart failure. See Table 2 , Feasibility Column, Size/Scope of Review Section for the citations of included studies. 
Value
The potential for value is uncertain. The nominator will use a new AHRQ systematic review to disseminate the findings to their health systems constituency. Whether the new review will be used to inform decision-making is uncertain. There are many other factors that may also affect the decisions to implement bundled payments beyond the evidence and these factors are beyond the control of health systems alone.
Summary of Findings
 This nomination meets all selection criteria.  We found two in-process reviews but they will not cover not cover the breadth of clinical conditions of the nomination.  The evidence base of a new review would likely be small and heterogeneous.  The potential for value is uncertain. Whether the new review will be used to inform health systems payment models decision-making is uncertain
